NCT01638533
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction treatment 1 active_not_recruiting NCT01940809
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery treatment 1 terminated NCT03326258
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery treatment 1 / 2 withdrawn NCT02304458
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas treatment 1 / 2 completed NCT02097225
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 unknown_status NCT01807182
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT01955460
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma treatment 1 active_not_recruiting NCT03325101
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery treatment 1 / 2 completed NCT01134614
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 active_not_recruiting NCT01258855
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT01480154
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer treatment 1 active_not_recruiting NCT03425461
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma treatment 1 terminated NCT02339571
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma treatment 2 / 3 recruiting NCT02910700
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma treatment 2 active_not_recruiting NCT02129075
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma treatment 2 completed NCT01303341
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma treatment 1 active_not_recruiting NCT02965716
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma treatment 2 active_not_recruiting NCT01740557
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma treatment 1 / 2 completed NCT03021460
Pembrolizumab and Ibrutinib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery No drug interventions treatment 1 active_not_recruiting NCT02196181
Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery treatment 2 active_not_recruiting